Search
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalIn preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile.
LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalPatients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss.
VA-MENGOC-BC®
go.drugbank.com/drugs/DB15800ExperimentalVA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine.
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].
Omburtamab
go.drugbank.com/drugs/DB15635InvestigationalCD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours. Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for us...
DDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Imexon
go.drugbank.com/drugs/DB05003InvestigationalImexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a c...
Fucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalIn vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer.
Coronavirus-Like Particle COVID-19 Vaccine
go.drugbank.com/drugs/DB15852ExperimentalIn July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine.